Impaired fatty acid oxidation in children on valproic acid and the effect of L‐carnitine
Нарушение бета-окисления жирных кислот у детей на вальпроевой кислоте и влияние L-карнитина
1993-11-01
SCID: 54.1/g4djp9f4
Discuss with AI
L-carnitine supplementationacylcarnitine ratiodicarboxylic acidsfatty acid oxidationvalproic acid
Figures from the paper
Abstract (AI)
Fatty acid oxidation was studied in 12 patients (aged 3 to 19 years) receiving valproic acid (VPA), predominantly as monotherapy, before and after 1 month of L-carnitine supplementation (50 mg/kg/day po) in order to determine whether L-carnitine plays a role in preventing the hepatotoxic effects of this drug. Five of these patients were also studied prior to VPA treatment. Only one patient taking VPA had an abnormally low plasma free carnitine. Acyl-/free carnitine ratios were elevated in five patients on VPA and normalized after L-carnitine supplementation. Mean plasma concentrations of free fatty acids, beta-OH-butyrate, and cumulative excretion of 13CO2 after administration of 1-13C-octanoic acid were not changed by VPA or L-carnitine treatment. Urinary dicarboxylic acids, acylglycines, and octanoylcarnitine were elevated during VPA therapy and unaltered by L-carnitine. These results suggest that, in patients at low risk for VPA-induced hepatotoxicity (patients aged > 2 years and taking VPA as monotherapy), VPA causes metabolic abnormalities resembling those found in inborn errors of mitochondrial beta-oxidation which are not corrected by L-carnitine.
Key Findings
1
Acyl-/free carnitine ratios were elevated in five patients on VPA and normalized after one month of L-carnitine (50 mg/kg/day) supplementation.
2
In low-risk patients (>2 years old on VPA monotherapy), L-carnitine did not correct VPA-induced metabolic abnormalities linked to impaired fatty acid oxidation.
3
Mean plasma free fatty acids, beta-hydroxybutyrate, and 13CO2 cumulative excretion after 1-13C-octanoic acid were unchanged by VPA or by L-carnitine.
4
Only one patient on VPA had abnormally low plasma free carnitine; most did not show frank carnitine deficiency.
5
Urinary dicarboxylic acids, acylglycines, and octanoylcarnitine were elevated during VPA therapy and were not altered by L-carnitine supplementation.
6
Valproic acid (VPA) therapy in children aged 3–19 induces metabolic abnormalities resembling mitochondrial beta-oxidation defects.
Research Object
Children (aged 3–19 years) receiving valproic acid therapy
Research Subject
Impaired fatty acid (mitochondrial beta-) oxidation and related metabolic abnormalities and the effect of L‑carnitine supplementation on these abnormalities
Publication Details
Publication Date
1993-11-01
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest